TEAD1 and intrahepatic cholangiocarcinoma: For instance, in cancers, miR‐590‐3p suppresses hepatocellular carcinoma growth by targeting TEAD1 (Ge & Gong, 2017), inhibits epithelial–mesenchymal transition in intrahepatic cholangiocarcinoma by targeting SIP1 (Zu et al., 2017), and represses migration, invasion, and epithelial–mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2 (Pang, Zheng, Zhao, Xiu, & Wang, 2015).